benzyl 4-<(tert-butyloxycarbonyl)methoxy>-1-piperidinecarboxylate | 144412-43-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-<(tert-butyloxycarbonyl)methoxy>-1-piperidinecarboxylate
• 英文别名: t-butyl 2-[(1-benzyloxycarbonyl-4-piperidinyl)oxy]acetate；benzyl 4-(2-t-butoxy-2-oxoethoxy)piperidine-1-carboxylate；benzyl 4-(2-(tert-butoxy)-2-oxoethoxy)piperidine-1-carboxylate；t-Butyl 2-(1-benzyloxycarbonyl-4-piperidyl)oxyacetate；N-benzyloxycarbonyl-4-[(t-butoxy carbonyl) methoxy]-piperidine；t-butyl 1-(benzyloxycarbonyl)piperidin-4-yloxyacetate；t-butyl [N-benzyloxycarbonyl-4-piperidinyloxy]acetate；benzyl 4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]piperidine-1-carboxylate
• CAS: 144412-43-1
• 化学式: C₁₉H₂₇NO₅
• 分子量: 349.427
• InChiKey: AFUXOWZWAJULFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl 4-<(tert-butyloxycarbonyl)methoxy>-1-piperidinecarboxylate 在 palladium on activated charcoal N-甲基吗啉 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 、 氢气 、 四丁基硫酸氢铵 、 碳酸氢钠 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 39.0h， 生成 2-[1-[2-[(4-甲脒基苯甲酰基)氨基]-3-(4-羟基苯基)丙酰]哌啶-4-基]氧基乙酸
  参考文献：
  名称：

  低分子量非肽纤维蛋白原受体拮抗剂。

  摘要：

  四肽H-Arg-Gly-Asp-Ser-OH（1）（RGDS）代表血纤维蛋白原对其血小板受体GP IIb-IIIa（整联蛋白alpha IIb beta 3）的识别序列，是开发GSH的主要化合物。高效和选择性的纤维蛋白原受体拮抗剂。用对-d基苯丙氨酸替换N-末端精氨酸或用间氨基苯甲酸替换Gly部分，使得化合物在GP IIb-IIIa的活性和选择性方面优于紧密连接的玻连蛋白受体αv beta 3.通过随机筛选[（对-氨基苯磺酰胺基）乙基]-对-苯氧基乙酸衍生物已鉴定为纤维蛋白原受体拮抗剂。

  DOI：

  10.1021/jm00101a017
• 作为产物：
  描述：

  氯甲酸苄酯 在 sodium hydroxide 、 四丁基硫酸氢铵 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 37.0h， 生成 benzyl 4-<(tert-butyloxycarbonyl)methoxy>-1-piperidinecarboxylate
  参考文献：
  名称：

  Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation

  摘要：

  The objective of this work was to synthesize cyclic prodrug 2 derived from the parent RGD peptidomimetic 1 and to evaluate its chemical and enzymatic stabilities and antithrombic activity. Cyclic prodrug 2 was formed to improve the cell membrane permeation of RGD peptidomimetic 1 by transiently masking the unfavorable physicochemical properties of compound 1. Cyclic prodrug 2 was synthesized by linking the amino and carboxylic acid groups of parent 1 via the (acyloxy)alkoxy promoiety. The prodrug-to-drug conversion of cyclic prodrug 2 was evaluated in isolated esterase and human plasma in the absence and presence of the esterase inhibitor paraoxon. The rate of hydrolysis of cyclic prodrug 2 was significantly faster in plasma (t(1/2) = 33.5 +/- 0.6 min) than in PBS (t(1/2) = 314 +/- 11 min). Cyclic prodrug 2 was converted by esterase to the parent compound 1 and this conversion was inhibited by an esterase inhibitor, paraoxon. The IC50 (4 muM) of cyclic prodrug 2 was higher than the IC50 (1.9 muM) of parent drug 1. The antithrombic activity of cyclic prodrug 2 depends on the incubation time in platelet-rich plasma; the activity increases with incubation time, suggesting that the prodrug-to-drug conversion is time-dependent and mediated by esterase. Cyclic prodrug 2 was more stable under acidic and neutral conditions than under basic conditions, suggesting that handling and formulation of this prodrug should be undertaken under acidic conditions. (C) 2002 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(02)00013-5

文献信息

• Carboxylic acid compound having condensed ring, salt thereof and
  申请人：The Green Cross Corporation

  公开号：US05635527A1

  公开（公告）日：1997-06-03

  A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.

  一种具有稠环结构的新型羧酸化合物，其由公式(I)表示：##STR1##，其中每个符号如说明书中所定义，其药理上可接受的盐，药物组合物及其药理用途。本发明的具有稠环结构的新型羧酸化合物及其药理上可接受的盐，在包括人类在内的哺乳动物中具有卓越的GPIIb/IIIa拮抗活性；可以通过口服给药；在血液中具有长效且毒性低；并且副作用较小。因此，它们对于预防治疗血栓性疾病和其他疾病非常有用。
• ＢＥＴ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途
  申请人：田辺三菱製薬株式会社

  公开号：WO2020009176A1

  公开（公告）日：2020-01-09

  がん細胞に対する細胞傷害作用、がん細胞におけるＢＥＴ蛋白質の分解を誘導する作用、およびＢＥＴ蛋白質とアセチル化ヒストンとの結合阻害作用に優れ、抗がん剤、ＢＥＴ蛋白質の分解誘導剤及びＢＥＴ蛋白質阻害剤として有用な化合物を提供すること。下記一般式（Ｉ）で表される化合物又はその薬理学的に許容される塩。｛式中、各記号は明細書中で定義した通りである。｝

  对癌细胞具有细胞损伤作用，诱导癌细胞中BET蛋白质的降解作用，以及优越的BET蛋白质与乙酰化组蛋白结合抑制作用，提供作为抗癌药物、BET蛋白质降解诱导剂和BET蛋白质抑制剂有用的化合物。该化合物或其药理学上可接受的盐由下述通用式（I）表示。式中，各符号如在说明书中定义。}
• Amino acid derivatives
  申请人：Hoffmann-La Roche Inc

  公开号：US05378712A1

  公开（公告）日：1995-01-03

  N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or control of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion.

  N-酰基-α-氨基羧酸衍生物的化学式为##STR1##，其中L，R'至R"'和Q的含义如描述中所示，可用于治疗或控制由粘附蛋白结合到血小板以及血小板聚集和细胞间黏附引起的疾病。
• TRICYCLIC COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1939205A1

  公开（公告）日：2008-07-02

  The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2', R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.

  本发明涉及一种三环化合物，每种化合物由以下式（I）表示：（其中，R1、R2、R2'、R3、R4、X、Y和Z的含义与规范中定义的含义相同）；以及含有该化合物的药物。由于根据本发明的化合物表现出优异的角鲨烯合酶抑制作用和胆固醇合成抑制作用，因此它们可用作哺乳动物（包括人类）的疾病预防和/或治疗药物，例如高脂血症，如高胆固醇血症、高甘油三酯血症、低高密度脂蛋白胆固醇血症和/或动脉粥样硬化。
• 2,3-diaminopropionic acid derivative
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05707994A1

  公开（公告）日：1998-01-13

  The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

  本发明涉及式（1）的2,3-二氨基丙酸衍生物：##STR1##或其药用可接受的盐。本发明的化合物可用作血小板聚集抑制剂、癌转移抑制剂、伤口愈合剂或骨吸收抑制剂。